Physician profile
Stuart Selonick
NPI 1457389561
$5,836.10
in general payments reported to CMS, 2019-2025
58 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $210 · 2021: $12.71 · 2022: $37.45 · 2023: $89.22 · 2024: $1,835 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $697.69 | 2019-2025 | |
| Pfizer INC. | $433.26 | 2019-2025 | |
| Abbvie INC. | $359.52 | 2019-2025 | |
| Janssen Biotech, INC. | $326.31 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $300.67 | 2019-2024 | Opdivo, Augtyro, Krazati |
| Astrazeneca Pharmaceuticals Lp | $296.28 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Celgene Corporation | $280.87 | 2019-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $260.17 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genzyme Corporation | $226.06 | 2019-2025 | |
| Beone Medicines USA, INC. | $181.31 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $178.03 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $166.21 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
| Array Biopharma INC | $120.59 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Daiichi Sankyo INC. | $102.35 | 2019-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $102.13 | 2019-2025 | Verzenio |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Selonick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.